The largest database of trusted experimental protocols

7 protocols using cd45 pc7

1

Flow Cytometry Analysis of T Cell Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols

Flow cytometry: T cell subsets were identified using multicolor flow cytometry with standard techniques on the Navios EX flow cytometer (Beckman Coulter, Sykesville, MD, United States). Whole blood samples were drawn from patients at the scheduled time points (T0, T3, and T6), collected in EDTA tubes, and processed for the evaluation of lymphocyte count and their subpopulations. T lymphocyte subsets determined were CD3+CD4+, CD3+CD8+, CD3-CD16+CD56+, CD3+CD4+CD28-, and CD3+CD8+CD28-, using the following monoclonal antibodies: CD3-FITC (clone: UCHT1; Beckman Coulter), CD16 (clone: 3G8; Beckman Coulter), CD56 clone: N901(NKH-1)-PE; Beckman Coulter), CD4-APC (clone: 13B8.2; Beckman Coulter), CD8 PC5.5 (clone: B9.11l Beckman Coulter), CD28-ECD (clone: CD28.2; Beckman Coulter), and CD45-PC7 (clone: J33; Beckman Coulter). Peripheral blood mononuclear cells were obtained by Ficoll density gradient centrifugation. Immunophenotyping of Tregs was performed with the combination of the following monoclonal antibodies: CD45-PC7 (clone: J33; Beckman Coulter), CD4-FITC (clone: 13B8.2; Beckman Coulter), CD25-PC5 (clone: B1.49.9; Beckman Coulter), and FOXP3-PE (clone: 259D; Beckman Coulter).
+ Open protocol
+ Expand
2

Comparative Analysis of hBM-MSCs and hWJ-MSCs Phenotypes

Check if the same lab product or an alternative is used in the 5 most similar protocols
hBM-MSCs and hWJ-MSCs were detached and counted; 1 × 105 cells were incubated at RT for 20 min with the following directly conjugated mouse-anti human antibodies: CD90 FITC (Beckman Coulter, Fullerton, CA, USA), CD73 APC (Miltenyi Biotec, Gladbach, Germany), CD105 PE (Beckman Coulter, Fullerton, CA, USA), CD45 PC7 (Beckman Coulter, Fullerton, CA, USA), HLA class-II FITC (Beckman Coulter, Fullerton, CA, USA), CD14 PC7 (Beckman Coulter, Fullerton, CA, USA), and CD34 PE (Beckman Coulter, Fullerton, CA, USA). The isotype-matched immunoglobulins IgG1 FITC (Beckman Coulter, Fullerton, CA, USA), IgG1 PE (Beckman Coulter, Fullerton, CA, USA), IgG1 APC (Beckman Coulter, Fullerton, CA, USA), and IgG1 PC7 (Beckman Coulter, Fullerton, CA, USA) were used as negative controls under the same conditions. At least 15,000 total events were acquired with a BD FACSVerse flow cytometer (Becton Dickinson, BD, NJ, USA). Further analysis and plots were generated using the BD FACSuite analysis software. Statistics are summarized in Table S1 (Supplementary Materials).
+ Open protocol
+ Expand
3

SRRM2 Expression in Tumor Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Heparin-anticoagulated bone marrow and peripheral blood specimens were collected, and two tubes were labeled in parallel for each specimen. Adjust the number of nucleated cells in each tube to 5–8 × 105. Add mouse anti-human SRRM2-specific recombinant antibody and matching isotype control antibody to two parallel tubes and incubate with all cells in the sample. After incubation at room temperature for 30 min, add 1.5 ml of saline and wash 3 times, centrifuge at 300 g/5 min and resuspend in 200 μL saline. Goat anti-rat IgG polyclonal to FITC fluorescent antibody (Abcam, batch ab150165, Cambridge, UK) and other fluorescent-labeled monoclonal antibodies (CD138-PE, CD38-APC,CD45-PC7, Beckman Coulter, Miami, FL, USA) were added, incubated for 15 min, and then treated with NH4Cl for 10 min for flow cytometry analysis. For the detection of all clinical samples, we uniformly used a flow cytometry protocol with four-color fluorescent labeling (FITC, PE, APC, and PC7) to analyze the expression of SRRM2 in tumor cells and other normal blood cells. Data acquisition and analysis were performed using a flow cytometer (Cytoflex S, Beckman Coulter) and CytExpert software (Beckman Coulter). A minimum of 105 nucleated cells and 500 target cells were obtained for most samples. For samples with fewer target cells, we obtained more cells by centrifugation or extended collection time.
+ Open protocol
+ Expand
4

Profiling Gut-Associated Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
PBMCs from UC patients and healthy controls were harvested and stained in duplicate for CD45-PC7, CD3-ECD, CD8-PE, CD4-FITC, CD19-PC5, CD38-FITC, CD27-PC7, CD86-PE (Beckman Coulter, Brea, CA), CXCR5-PC5 and ICOS-PE (eBioscience, San Diego, CA) at room temperature for 30 min. After being washed with PBS, the cells were characterized by flowcytometry analysis using the Beckman Coulter Cytomics FC500 (Beckman Coulter). Cells stained with separate antibodies were defined as certain TFH cells (CD4+ CXCR5+ TH cells and CD4+CXCR5+ICOS+ TH cells) and subsets of B cells (CD38+CD19+ B cells, CD86+CD19+ B cells and CD27+CD19+ B cells). Data were analysed with a CXP Analysis Cytometer (Beckman Coulter).
+ Open protocol
+ Expand
5

Measuring Immunomodulation of BM-MSC

Check if the same lab product or an alternative is used in the 5 most similar protocols
Immunomodulation analysis was performed by co-culturing BM-MSC with peripheral blood mononucleated cells (PBMC) isolated by density gradient centrifugation and labeled with Carboxyfluorescein Succinimidyl ester (Celltrace CFSE Cell Proliferation Kit, Invitrogen, Carlsbad, CA, USA) at the PBMC:BM-MSC ratio of 20:1, 10:1 and 5:1. PBMC were stimulated with 500 U/ml of Interleukin 2 (Proleukin, Novartis Pharma, Varese, I) and 0.5 µg/ml antibody anti CD3 (Miltenyi Biotec, Bergisch Gladbach, DE). PBMC unstimulated and activated in absence of effector cells were used as controls. After 6 days, PBMC were labeled with CD45 PC7 (Beckman Coulter Fullerton, CA, USA) and 7-aminoactinomycin D (7-AAD) (Invitrogen Carlsbad, CA, USA) and analyzed with a FC500 flow cytometer (Beckman Coulter Fullerton, CA, USA). The inhibition of the PBMC CD45+ 7AAD-cell subset induced by BM-MSC was expressed according to the following formula: (%CFSE+activated PBMC in absence of BM-MSC-%CFSE+activated PBMC in presence of BM-MSC)×100%CFSE+activated PBMC in absence of BM-MSC
+ Open protocol
+ Expand
6

Flow Cytometry Immunophenotyping Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies directed against the following human cell surface proteins were obtained from commercial sources: CD45-PC7, CD45-FITC, CD3-PE, CD5-ECD, CD34-FITC, CD19-APC, CD23-PE (Beckman Coulter, Miami, FL) CD133-PE and CD133-APC (Miltenyi Biotec, Auburn, CA). Stained samples were washed in PBS containing 2% FBS and 7-aminoactinomycin (7-AAD). A minimum of 20,000 cells (unless noted otherwise) was analyzed on a Coulter Cytomics FC500 flow cytometer (Beckman Coulter, Miami, FL). All analysis of normal and lymphoma cells were gated on human CD45+ cells. Sequential gates were set to include only viable cells and quadrant markers were set to exclude at least 99.9% of cells labeled with the appropriate fluorochrome labeled isotype controls.
+ Open protocol
+ Expand
7

Immunophenotypic Characterization of hBM-MSCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
Flow cytometry was used to immunophenotypically characterize hBM-MSCs at P2, by means of anti-CD73 (AD2; Becton Dickinson-Pharmingen, San Diego, CA, USA), anti-CD90 (F15.42; Immunotech/Coulter), anti-CD105 (SN6; Caltag, Burlingame, CA, USA), anti-CD45 (IMMU19.2; Immunotech/Coulter), anti-CD14 (RMO52; Immunotech/Coulter), and anti-CD34 (QBend10; Beckman-Coulter) monoclonal antibodies [37 (link)]. Freshly isolated hPBMCs were stained and immunophenotypically characterized with the antibodies CD45-PC7 and CD14-PE (both from Beckman-Coulter, California, CA, USA). Stained samples were then analyzed for monocytic population CD45+ and CD14+ cells. Analysis was performed in a Cytomics FC500 flow cytometer (Beckman Coulter, California, CA, USA).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!